Navigation Links
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Date:4/1/2008

IRVINE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported topline results of a clinical trial of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once-daily) 0.18% formulation, a new formulation of ISTA's ocular, non- steroidal anti-inflammatory agent. The findings demonstrated equivalence between the 0.18% formulation and ISTA's 0.09% formulation of Xibrom given once daily in achieving the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery. The data also showed no statistically significant difference between the two formulations in achieving the secondary efficacy endpoints of elimination of ocular pain and mean reduction of markers of inflammation (inflammatory cells and flare). In addition, the results indicated both formulations of bromfenac produced a low overall incidence of ocular adverse events.

"We undertook this trial in connection with our Xibrom QD NDA application, which was submitted to the FDA in December 2007. The nearly identical performance of the two concentrations was unexpected and inconsistent with the previously available data. The results suggest the 0.09% formulation is near the top of the dose-response curve," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "Our next steps are to complete the data analysis and speak with the FDA to determine a possible path forward, as well as consider other options in terms of new Xibrom products. Part of our discussions will be to review the possibility of a label change for the currently marketed 0.09% formulation of Xibrom so that it can be administered once-daily."

Conference Call

ISTA will host a conference call
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
8. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
11. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... , Nov. 25, 2014 ... focused on the development of mobile diagnostic ... testing in hospital and pre-hospital settings, today ... (ISO) 13485:2003 certification.  The certification was awarded ... of the world,s leading certification bodies. ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... 26, 2014 (HealthDay News) -- Most babies and young ... the U.S. Food and Drug Administration says. Over-the-counter ... to children younger than 2 because they could cause ... American adults average about three colds a year, ... a cold, parents might want to give them pain ...
(Date:11/27/2014)... 27, 2014 In order to enable people ... Fla., designed an easy way to avoid touching a toilet ... then created a prototype of the patent-pending Toilet Tamer, a ... toilet seat and/or lid in a more sanitary manner. It ... of germs. Overall, it promotes good hygiene and peace of ...
(Date:11/27/2014)... 2014 Now that Thanksgiving is finally ... launched, Emassagechair.com has announced its eagerly awaited, ... , Negotiating on behalf of their customers, and ... brands, Emassagechair.com has generated significant buzz in the industry ... discounts yet. , Shoppers are excited for significant savings ...
(Date:11/27/2014)... VogueQueen.com is making every effort to ... the world. As the premier online supplier of elegant ... to release a huge selection of sexy prom dresses ... is also providing many beautiful styles in its product ... at discounted prices. , “VogueQueen.com hopes to provide a ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2
... mid-October, ahead of vaccine delivery , THURSDAY, Sept. 10 (HealthDay ... flu outbreak is expected in October, but a planned vaccine ... suggests. , The first batch of the new H1N1 vaccine, ... according to the U.S. Centers for Disease Control and Prevention. ...
... Boston Scientific Corporation (NYSE: BSX ) is scheduled to ... , Ray Elliott, President and Chief Executive Officer ... participate in a 35-minute discussion about the Company on Tuesday, September ... , A live webcast of this discussion will be ...
... ... reconstruction, quicker recovery and more natural knee motion post-surgery , ... Evanston, Illinois (Vocus) -- NorthShore University ... use a new and innovative robotic technology for minimally-invasive partial knee replacement ...
... , , WOODCLIFF ... today announced that it has received final approval from the U.S. ... nateglinide tablets. Nateglinide is a generic version of Novartis, Starlix(R). ... to IMS Health data. Par will begin shipping the 60mg ...
... , , WARSAW, Ind., ... leading independent provider of products to the global orthopedic device industry and ... Executive Officer, and Fred L. Hite, Senior Vice President and Chief Financial ... at the Grand Hyatt Grand Central Hotel in New York City on ...
... , , NEW DELHI, Sept. 10 ... in India -- today announced an inspiring list of speakers for the ... theme of TEDIndia is "The Future Beckons." , , ... from diverse disciplines. Doctor and researcher Hans Rosling will share ...
Cached Medicine News:Health News:Swine Flu Shots May Come Too Late to Stem Fall Outbreak: Study 2Health News:Swine Flu Shots May Come Too Late to Stem Fall Outbreak: Study 3Health News:Boston Scientific to Participate in Morgan Stanley Global Healthcare Conference 2Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 2Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 3Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 4Health News:Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R) 2Health News:Symmetry Medical to Present at UBS Global Life Sciences Conference 2Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 2Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 3Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 4Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 5Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 6
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
Medicine Products: